{"success":true,"data":{"pressRelease":{"id":"56013","rtpr_id":"nPregds97a","ticker":"1779","exchange":"HKEX","all_tickers":["1779"],"title":"China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange","author":"PR Newswire","published_at":"2026-06-05T09:05:12.886Z","article_body":"China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases\nLongBio Pharma Lists on Hong Kong Stock Exchange\nPR Newswire\n\nSHANGHAI, June 5, 2026\n\nSHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of\nQiming Venture Partners and a leading innovative drug developer for allergic\nand autoimmune diseases in China, listed on the Hong Kong Stock Exchange on\nJune 5, 2026 Beijing time, marking the seventh IPO for Qiming Venture Partners\nthis year. LongBio Pharma (01779.HK) issued its shares at a price of HK$96.06\nper share and opened at HK$144.30 per share with a market capitalization of\nHK$10.7 billion.\n\nQiming Venture Partners invested in the B2 round of financing of LongBio\nPharma as the lead-investor in 2024 and invested in the C round as the\nco-lead-investor in 2025. Before the IPO, Qiming Venture Partners held a 4.27\npercent stake in LongBio Pharma as one of its major institutional investors.\n\nFounded in 2020, LongBio Pharma focuses on in-house discovery and development\nof biopharmaceuticals targeting on allergic and autoimmune diseases. Its\nfounding team has rich experience in its field and has achieved outstanding\nresults in discovery of drugs, clinical development, and registration\nprocedures. Dr. Sun Naichao, co-founder of LongBio Pharma, is the key\noriginal inventor of omalizumab, the world's first pioneering anti-IgE\nantibody. He has been devoting himself to the allergic diseases for decades\nand is a pioneering scientist in development of drugs for allergic diseases.\nDr. Liu Heng, co-founder, Chairman and CEO of the firm, has over 15 years of\nexperience in research and development and commercialization of\nbiopharmaceutical drugs and has played a pivotal role in both domestic and\ninternational programs of development of several innovative drugs.\n\nLongBio Pharma has developed a comprehensive product pipeline for biologic\ntreatments targeting rhinology, dermatology, respiratory, hematology,\nnephrology and other autoimmune diseases. The firm's core product LP-003 is a\nnovel anti-IgE antibody. Its main function is to block free IgE in the blood\nand tissues and thus inhibit the occurrence of IgE-mediated allergic\nreactions. According to the top-line results, LP-003 exhibited significantly\nbetter efficacy than omalizumab in the treatment of chronic spontaneous\nurticaria (CSU). LP-005, a major product of LongBio Pharma, is a novel\nbi-functional complement antibody-fusion protein targeting both C5 and C3b,\nhas leading potential globally, and shows therapeutic potential compared with\nsingle-target complement inhibitors. \n\n\"In 2024, omalizumab was approved in the United States, opening up\ncommercialization opportunities. The prevalence of allergic diseases such as\nallergic rhinitis, asthma, and chronic urticaria has been rising in China.\nBased on clinical needs, technical barriers, team strength, and market\ninflection points, Qiming Venture Partners chose to invest in LongBio Pharma.\nThe listing of LongBio Pharma is a key milestone for the company's transition\nfrom the laboratory to commercialization, and the firm is expected to grow\ninto a leading enterprise in the field of allergic diseases in China. LongBio\nPharma is also an original innovation investment made by Qiming Venture\nPartners during the medical capital winter, which confirms Qiming Venture\nPartners' resilience in navigating through industry cycles and its independent\njudgment ability for projects. Qiming Venture Partners will continue to focus\non addressing unmet clinical needs and always pursue investments in\ncutting-edge medical innovation with global competitiveness,\" Dr. Kan Chen, a\npartner of Qiming Venture Partners and the co-lead of the Qiming's\ninvestments in the healthcare sector, said.\n\nAbout Qiming Venture Partners\n\nQiming Venture Partners was founded in 2006. Currently, Qiming Venture\nPartners manages eleven US Dollar funds and seven RMB funds with $9.5 billion\nin capital raised. Since our establishment, we have invested in outstanding\ncompanies in the Technology and Healthcare industries at the early and growth\nstages.\n\nSince our debut, we have backed over 580 fast-growing and innovative\ncompanies. Over 210 of our portfolio companies have achieved exits through\nIPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock\nExchange, or through M&A or other means. There are also over 80 portfolio\ncompanies that have achieved unicorn or super unicorn status.\n\nMany of our portfolio companies are today's most influential firms in their\nrespective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock,\nHesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren\nTechnology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino\nBiologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech,\nInsilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics,\nLaNova Medicines, StepFun, among many others.\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/chinas-leading-innovative-drug-developer-for-allergic-and-autoimmune-diseases-longbio-pharma-lists-on-hong-kong-stock-exchange-302792533.html\n\n\n\nAnna Qiu, Tel: (86 21) 6101 6522, Fax: (86 21) 6101 6512, Email: anna.qiu@qimingvc.com\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPregds97a","title":"China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange","author":"PR Newswire","ticker":"1779","created":"2026-06-05T09:05:12.886Z","tickers":["1779"],"exchange":"HKEX","article_body":"China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases\nLongBio Pharma Lists on Hong Kong Stock Exchange\nPR Newswire\n\nSHANGHAI, June 5, 2026\n\nSHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of\nQiming Venture Partners and a leading innovative drug developer for allergic\nand autoimmune diseases in China, listed on the Hong Kong Stock Exchange on\nJune 5, 2026 Beijing time, marking the seventh IPO for Qiming Venture Partners\nthis year. LongBio Pharma (01779.HK) issued its shares at a price of HK$96.06\nper share and opened at HK$144.30 per share with a market capitalization of\nHK$10.7 billion.\n\nQiming Venture Partners invested in the B2 round of financing of LongBio\nPharma as the lead-investor in 2024 and invested in the C round as the\nco-lead-investor in 2025. Before the IPO, Qiming Venture Partners held a 4.27\npercent stake in LongBio Pharma as one of its major institutional investors.\n\nFounded in 2020, LongBio Pharma focuses on in-house discovery and development\nof biopharmaceuticals targeting on allergic and autoimmune diseases. Its\nfounding team has rich experience in its field and has achieved outstanding\nresults in discovery of drugs, clinical development, and registration\nprocedures. Dr. Sun Naichao, co-founder of LongBio Pharma, is the key\noriginal inventor of omalizumab, the world's first pioneering anti-IgE\nantibody. He has been devoting himself to the allergic diseases for decades\nand is a pioneering scientist in development of drugs for allergic diseases.\nDr. Liu Heng, co-founder, Chairman and CEO of the firm, has over 15 years of\nexperience in research and development and commercialization of\nbiopharmaceutical drugs and has played a pivotal role in both domestic and\ninternational programs of development of several innovative drugs.\n\nLongBio Pharma has developed a comprehensive product pipeline for biologic\ntreatments targeting rhinology, dermatology, respiratory, hematology,\nnephrology and other autoimmune diseases. The firm's core product LP-003 is a\nnovel anti-IgE antibody. Its main function is to block free IgE in the blood\nand tissues and thus inhibit the occurrence of IgE-mediated allergic\nreactions. According to the top-line results, LP-003 exhibited significantly\nbetter efficacy than omalizumab in the treatment of chronic spontaneous\nurticaria (CSU). LP-005, a major product of LongBio Pharma, is a novel\nbi-functional complement antibody-fusion protein targeting both C5 and C3b,\nhas leading potential globally, and shows therapeutic potential compared with\nsingle-target complement inhibitors. \n\n\"In 2024, omalizumab was approved in the United States, opening up\ncommercialization opportunities. The prevalence of allergic diseases such as\nallergic rhinitis, asthma, and chronic urticaria has been rising in China.\nBased on clinical needs, technical barriers, team strength, and market\ninflection points, Qiming Venture Partners chose to invest in LongBio Pharma.\nThe listing of LongBio Pharma is a key milestone for the company's transition\nfrom the laboratory to commercialization, and the firm is expected to grow\ninto a leading enterprise in the field of allergic diseases in China. LongBio\nPharma is also an original innovation investment made by Qiming Venture\nPartners during the medical capital winter, which confirms Qiming Venture\nPartners' resilience in navigating through industry cycles and its independent\njudgment ability for projects. Qiming Venture Partners will continue to focus\non addressing unmet clinical needs and always pursue investments in\ncutting-edge medical innovation with global competitiveness,\" Dr. Kan Chen, a\npartner of Qiming Venture Partners and the co-lead of the Qiming's\ninvestments in the healthcare sector, said.\n\nAbout Qiming Venture Partners\n\nQiming Venture Partners was founded in 2006. Currently, Qiming Venture\nPartners manages eleven US Dollar funds and seven RMB funds with $9.5 billion\nin capital raised. Since our establishment, we have invested in outstanding\ncompanies in the Technology and Healthcare industries at the early and growth\nstages.\n\nSince our debut, we have backed over 580 fast-growing and innovative\ncompanies. Over 210 of our portfolio companies have achieved exits through\nIPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock\nExchange, or through M&A or other means. There are also over 80 portfolio\ncompanies that have achieved unicorn or super unicorn status.\n\nMany of our portfolio companies are today's most influential firms in their\nrespective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock,\nHesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren\nTechnology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino\nBiologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech,\nInsilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics,\nLaNova Medicines, StepFun, among many others.\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/chinas-leading-innovative-drug-developer-for-allergic-and-autoimmune-diseases-longbio-pharma-lists-on-hong-kong-stock-exchange-302792533.html\n\n\n\nAnna Qiu, Tel: (86 21) 6101 6522, Fax: (86 21) 6101 6512, Email: anna.qiu@qimingvc.com\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-05T09:05:12.955892552Z","server_sent_at_ms":1780650312955},"received_at":"2026-06-05T09:05:13.009Z","source_url":null},"analysis":{"id":"45440","press_release_id":"56013","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"LongBio Pharma (01779.HK) listed on the Hong Kong Stock Exchange on June 5, 2026, issuing shares at HK$96.06.\n\nThe stock opened at HK$144.30, representing a 50% premium to the issue price and establishing a market capitalization of HK$10.7 billion.\n\nThe listing marks the company's transition from R&D to commercialization, backed by lead investor Qiming Venture Partners which holds a 4.27% stake.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"LongBio IPO pops 50% on day one; HK-listed biotech gains liquidity ahead of commercial launch."},"keyFigures":{"offeringPrice":96.06,"customDimensions":{"market_cap_hkd":"10.7 billion","qiming_stake_pct":4.27,"opening_price_hkd":144.3}},"quotedText":"The listing of LongBio Pharma is a key milestone for the company's transition from the laboratory to commercialization","namedEntities":{"people":[{"name":"Dr. Sun Naichao","role":"Co-founder"},{"name":"Dr. Liu Heng","role":"Chairman and CEO"},{"name":"Dr. Kan Chen","role":"Partner, Qiming Venture Partners"}],"products":["LP-003","LP-005","omalizumab"],"companies":[{"name":"LongBio Pharma","ticker":"01779.HK","relationship":"issuer"},{"name":"Qiming Venture Partners","relationship":"investor"}],"dollarAmounts":[{"amount":"HK$96.06","context":"IPO issue price per share"},{"amount":"HK$144.30","context":"Opening price per share"},{"amount":"HK$10.7 billion","context":"Market capitalization at open"},{"amount":"$9.5 billion","context":"Capital managed by Qiming Venture Partners"}]},"materialImpact":{"score":4,"reasoning":"Successful IPO on HKEX with a significant first-day pop (50%+ from issue price to open) and a $1.36B market cap. This is a major liquidity and valuation event for a pre-commercial biotech, though it is a standard listing rather than a binary FDA approval."},"tickerRelevance":{"others":[],"primary":"1779"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"ipo_listing","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"positive_open","retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"LongBio Pharma (01779.HK) listed on the Hong Kong Stock Exchange on June 5, 2026, issuing shares at HK$96.06.\n\nThe stock opened at HK$144.30, representing a 50% premium to the issue price and establishing a market capitalization of HK$10.7 billion.\n\nThe listing marks the company's transition from R&D to commercialization, backed by lead investor Qiming Venture Partners which holds a 4.27% stake.","key_figures":{"offeringPrice":96.06,"customDimensions":{"market_cap_hkd":"10.7 billion","qiming_stake_pct":4.27,"opening_price_hkd":144.3}},"named_entities":{"people":[{"name":"Dr. Sun Naichao","role":"Co-founder"},{"name":"Dr. Liu Heng","role":"Chairman and CEO"},{"name":"Dr. Kan Chen","role":"Partner, Qiming Venture Partners"}],"products":["LP-003","LP-005","omalizumab"],"companies":[{"name":"LongBio Pharma","ticker":"01779.HK","relationship":"issuer"},{"name":"Qiming Venture Partners","relationship":"investor"}],"dollarAmounts":[{"amount":"HK$96.06","context":"IPO issue price per share"},{"amount":"HK$144.30","context":"Opening price per share"},{"amount":"HK$10.7 billion","context":"Market capitalization at open"},{"amount":"$9.5 billion","context":"Capital managed by Qiming Venture Partners"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-05T09:05:25.115Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"ipo_listing","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"positive_open","retailFavoriteBoost":0}},"durationMs":12008,"modelName":"george-droid-qwen-72b"}}